Menu

Clinical Pearls

Dr Morganna Freeman outlines some of the criteria used in deciding which patients will most benefit from immunotherapy.
Dr Morganna Freeman discusses some of the ways immunotherapy has changed cancer care, including the expectation for long-term survival and how to treat patients in remission.
Dr Morganna Freeman considers the future application of treatment modalities and how they might be combined for optimal results.
Dr Morganna Freeman on the challenge of deciding when to treat a patient with immunotherapy.
Dr Morganna Freeman recommends that navigators develop a good triage system to effectively manage adverse events.
Dr Andrey Antov provides an overview of the role of Jackson Laboratory in the field of cancer genetic testing and in the education of nurses and navigators who co-manage patients at high risk or with a diagnosis of cancer.
Dr Andrey Antov muses on the evolution of genomics and how it could potentially impact targeted therapies and cancer care.
Dr Andrey Antov identifies situations in which people may want to consider genetic testing.
Dr Andrey Antov provides a useful metaphor to explain how genetic testing and genomic testing differ from one another and the purpose behind each type of testing.
Dr Andrey Antov notes that there is often confusion around genetic and genomic testing, due in part to a lack of genetic counselors, high costs, and the rate of adoption of new technologies.
Page 1 of 4
Results 1 - 10 of 35

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Thank you to our Corporate Sponsors and Alliance Partners!

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Industry Relations Council Member

    Industry Relations
    Council Member

  • National Alliance Partner

    National Alliance Partner

  • Health System Partner

    Health System Partner

  • Health System Partner

    Health System Partner

  • Health System Partner

    Health System Partner

  • Industry Relations Alliance Partner

    Industry Relations Alliance Partner

  • Industry Relations Alliance Partner

    Industry Relations Alliance Partner